Traders Union
All News
Cell therapy, regenerative medicine, and biotechnology development by Capricor Therapeutics

Advertiser Disclosure

Cell therapy, regenerative medicine, and biotechnology development by Capricor Therapeutics

Capricor Therapeutics, Inc. leadership engages at Miami CNS and NeuroMuscular Summit

Andreas Kristo
10.06.2026

Capricor Therapeutics, Inc. leadership engages at Miami CNS and NeuroMuscular Summit

Capricor Therapeutics, Inc. CEO Linda Marbán participated in the Oppenheimer CNS and NeuroMuscular Summit held in Miami, Florida. She joined industry leaders from Sarepta and Dyne on the panel ...

Capricor Therapeutics, Inc. to present at Goldman Sachs and Oppenheimer investor conferences in Miami

Oleg Tkachenko
08.06.2026

Capricor Therapeutics, Inc. to present at Goldman Sachs and Oppenheimer investor conferences in Miami

Capricor Therapeutics, Inc. will participate in two major investor conferences this week in Miami, aiming to engage with the financial community and share updates on its business and pipeline. ...

Capricor Therapeutics, Inc. advances research on preserving and protecting muscle at Orlando event

Ashutosh Sureka
22.05.2026

Capricor Therapeutics, Inc. advances research on preserving and protecting muscle at Orlando event

Capricor Therapeutics, Inc. is presenting today at the CureDuchenne FUTURES Conference in Orlando, Florida, focusing on cutting-edge developments in muscle preservation, protection, and ...

Capricor Therapeutics reports first quarter 2026 earnings and issues corporate update

Elena Nikulina
12.05.2026

Capricor Therapeutics reports first quarter 2026 earnings and issues corporate update

Capricor Therapeutics has released its financial results for the first quarter of 2026 and issued a corporate update. The announcement includes detailed information on the company’s current ...

Fourth quarter and full year 2025 earnings released, Capricor Therapeutics, Inc. outlines

Anastasiia Chabaniuk
12.03.2026

Fourth quarter and full year 2025 earnings released, Capricor Therapeutics, Inc. outlines

Capricor Therapeutics, Inc. has released its financial results for the fourth quarter and the full year 2025. The announcement comes as the company prepares for its scheduled quarterly ...

Capricor Therapeutics, Inc. resumes Deramiocel BLA review as FDA sets August 22, 2026 deadline

Olga Shendetskaya
10.03.2026

Capricor Therapeutics, Inc. resumes Deramiocel BLA review as FDA sets August 22, 2026 deadline

Capricor Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has resumed its review of the Biologics License Application (BLA) for Deramiocel, a therapy developed ...

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.